GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.26 USD | +0.28% |
|
-2.16% | -20.68% |
Financials (USD)
| Sales 2024 * | 27.58B | Sales 2025 * | 27.97B | Capitalization | 80.07B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M | Net income 2025 * | 6.37B | EV / Sales 2024 * | 3.55 x |
| Net Debt 2024 * | 17.9B | Net Debt 2025 * | 12.47B | EV / Sales 2025 * | 3.31 x |
| P/E ratio 2024 * |
177
x | P/E ratio 2025 * |
12.5
x | Employees | 18,000 |
| Yield 2024 * |
4.82% | Yield 2025 * |
5.05% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +0.28% | ||
| 1 week | -2.16% | ||
| Current month | -0.02% | ||
| 1 month | -1.91% | ||
| 3 months | -11.13% | ||
| 6 months | -17.24% | ||
| Current year | -20.68% |
1 week
62.07
65.55
1 month
62.0768.37
Current year
62.0787.87
1 year
62.0787.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +13.69% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 64.27 | +0.30% | 14,509,333 |
| 24-05-30 | 64.08 | +0.91% | 7,127,599 |
| 24-05-29 | 63.5 | -0.69% | 5,609,571 |
| 24-05-28 | 63.94 | -2.65% | 5,593,404 |
| 24-05-24 | 65.68 | -0.74% | 5,971,044 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.68% | 80.07B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- GILD Stock
